Skip to main content

BNP2: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Multiple-Dose Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered Nesiritide (recombinant human B-type natriuretic peptide) in Otherwise Healthy Obese Subjects

BNP2: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Multiple-Dose Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered Nesiritide (recombinant human B-type natriuretic peptide) in Otherwise Healthy Obese Subjects

Principal Investigator

Sponsor

Merck Sharp & Dohme

The purpose of this study is to: To test the safety and tolerability of two doses of nesiritide after both single and repeated dosing in otherwise healthy overweight subjects. To measure how much nesiritide gets into the blood and how long it takes the body to get rid of it and to obtain information on how chemicals and proteins in your blood change after taking nesiritide.